Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 8/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10193829 | 1.00 | KDR (0.42) | KDROPRM1OPRD1KMT2ANTRK1 | |
| SCHEMBL2065656 | 0.92 | KDR (0.45) | KDRKMT2ANTRK1LCK | |
| SCHEMBL2067918 | 0.88 | NTRK1 (0.42) | KDRNTRK1LCK | |
| SCHEMBL2067768 | 0.88 | NTRK1 (0.43) | KDRNTRK1LCK | |
| SCHEMBL10193864 | 0.87 | NTRK1 (0.41) | KDRNTRK1LCK | |
| SCHEMBL2065982 | 0.87 | KDR (0.40) | KDRNTRK1LCK | |
| Hydrochloric Acid SCHEMBL2067915 | 0.87 | NTRK1 (0.41) | KDRNTRK1LCK | |
| SCHEMBL2065114 | 0.86 | NTRK1 (0.40) | KDRNTRK1LCK | |
| SCHEMBL10193870 | 0.86 | KDR (0.41) | KDRNTRK1LCK | |
| Hydrochloric Acid SCHEMBL2066362 | 0.85 | KDR (0.41) | KDRNTRK1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2099794-B1 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2013-05-15 | — | — | EP | disclosed |
| US-8148400-B2 | Thiazolyl compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| US-20100048581-A1 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048581-A1 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS | ERBB2, TEC, TTBK1 | KDR 672/4885OPRM1 4723/4885OPRD1 4735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.